…
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
PharmaCyte Biotech is a clinical-stage company developing a cell-encapsulation platform (Cell-in-a-Box) to localize therapeutic activity, principally applied to pancreatic cancer with earlier-stage work in metabolic disease. Long-term growth may be driven by positive clinical trial results, regulatory progress, and partnerships or licensing that expand use of the platform. Investors may find the company attractive for its differentiated local prodrug activation approach that could improve tumor targeting and limit systemic toxicity if trials are successful.
The principal investment risks are high clinical and regulatory uncertainty for a single-platform, capital-intensive small company that currently lacks commercial revenues and may require additional financing, exposing shareholders to dilution and execution risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
| Income before tax | -19.42M | 30.66M | 0.33M | -4.32M | -4.24M |
| Net income | -19.42M | 30.66M | 0.33M | -4.32M | -4.09M |
| Selling general administrative | 4.91M | 3.94M | 6.11M | 5.99M | 3.70M |
| Selling and marketing expenses | - | - | 1.32M | - | - |
| Ebit | - | 26.28M | 0.33M | -6.46M | -4.39M |
| Ebitda | -5.30M | -4.38M | -6.52M | -4.32M | -4.24M |
| Depreciation and amortization | - | 4.38M | 6.52M | 2.14M | 0.15M |
| Operating income | -6.85M | -4.38M | -8.52M | -6.46M | -4.39M |
| Other operating expenses | 6.85M | 4.38M | 8.52M | 6.46M | 4.39M |
| Interest expense | - | - | - | 0.00M | 0.00M |
| Tax provision | 0.00M | 0.00M | - | - | - |
| Interest income | 0.73M | 1.42M | 3.40M | 1.94M | 0.16M |
| Net interest income | 0.73M | 1.42M | 3.40M | 1.94M | 0.16M |
| Income tax expense | - | - | -6.52M | -1.94M | -0.15M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 6.85M | 4.38M | 8.52M | 6.46M | 4.39M |
| Total other income expense net | -12.57M | 35.03M | 8.85M | 0.20M | 0.15M |
| Net income from continuing ops | -19.42M | 30.66M | 0.33M | -4.32M | -4.24M |
| Net income applicable to common shares | - | - | - | - | -4.24M |
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
| Total assets | 46.75M | 55.17M | 59.90M | 73.28M | 90.62M |
| Intangible assets | - | 1.55M | 1.55M | 3.55M | 3.55M |
| Other current assets | 0.10M | 3.14M | 0.26M | 0.11M | 0.09M |
| Total liab | 11.77M | 3.28M | 20.39M | 0.59M | 0.70M |
| Total stockholder equity | 33.29M | 51.89M | 39.51M | 72.69M | 89.92M |
| Other current liab | 0.56M | 2.52M | 6.69M | 0.46M | 0.50M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 1.27M | 0.00M | 11.87M | 0.00M | 0.00M |
| Retained earnings | -104.39M | -84.97M | -115.63M | -115.96M | -111.65M |
| Other assets | - | - | - | - | 0.01M |
| Cash | 18.60M | 15.17M | 50.18M | 68.04M | 85.40M |
| Total current liabilities | 0.83M | 2.91M | 7.42M | 0.59M | 0.70M |
| Net debt | -18.60M | -15.17M | -50.18M | -68.04M | -85.40M |
| Other stockholder equity | 137.71M | 136.88M | 143.29M | 188.67M | 201.58M |
| Total current assets | 37.42M | 22.38M | 50.44M | 68.15M | 85.49M |
| Long term investments | 0.00M | 22.47M | 0.00M | 1.57M | 1.57M |
| Net tangible assets | - | - | - | - | 86.37M |
| Short term investments | 18.48M | 0.37M | 0.00M | - | - |
| Net receivables | 0.24M | 3.70M | - | - | - |
| Accounts payable | 0.27M | 0.40M | 0.39M | 0.13M | 0.21M |
| Accumulated other comprehensive income | -0.02M | -0.02M | -0.02M | -0.02M | -0.02M |
| Non currrent assets other | 9.33M | 8.77M | 7.91M | 0.01M | 0.01M |
| Non current assets total | 9.33M | 32.79M | 9.46M | 5.13M | 5.13M |
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
| Investments | -3.00M | -7.00M | -5.00M | 0.00M | 0.00M |
| Change to liabilities | - | - | - | - | 0.03M |
| Total cashflows from investing activities | 2.00M | -7.00M | -5.00M | - | - |
| Net borrowings | - | - | - | - | -0.05M |
| Total cash from financing activities | 6.58M | -25.03M | -10.71M | -13.56M | 87.31M |
| Change to operating activities | - | - | - | - | -0.02M |
| Net income | -19.42M | 30.66M | 0.33M | -4.32M | -4.24M |
| Change in cash | 3.43M | -35.01M | -17.86M | -17.36M | 83.20M |
| Begin period cash flow | 15.17M | 50.18M | 68.04M | 85.40M | 2.20M |
| End period cash flow | 18.60M | 15.17M | 50.18M | 68.04M | 85.40M |
| Total cash from operating activities | -5.15M | -2.98M | -2.15M | -3.79M | -4.12M |
| Issuance of capital stock | 6.18M | 0.00M | 33.65M | 0.00M | 87.36M |
| Other cashflows from investing activities | 2000000.00M | - | -5.00M | - | - |
| Dividends paid | 0.25M | 1.13M | 22.46M | - | - |
| Sale purchase of stock | -0.40M | -25.03M | -44.36M | -13.56M | - |
| Other cashflows from financing activities | 6.18M | -21.36M | 17.49M | 0.00M | 87.31M |
| Change to netincome | - | - | - | - | 0.11M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -1.92M | 1.36M | 0.30M | -0.30M | 0.01M |
| Stock based compensation | 1.13M | 0.48M | 0.67M | 0.65M | 0.08M |
| Other non cash items | 15.07M | -35.47M | -3.46M | 0.17M | 0.03M |
| Free cash flow | -5.15M | -2.98M | -2.15M | -3.79M | -4.12M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PMCB PharmaCyte Biotech Inc |
- -% |
5.42 | - | 7.02 | 12904.41 | 0.12 | 14270.44 | -12.02 |
| NVO Novo Nordisk A/S |
-1.05 2.58% |
39.65 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.46 0.65% |
537.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.75 1.02% |
948.01 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169
917 595 2850
2
| Name | Title | Year Born |
|---|---|---|
| Mr. Carlos A. Trujillo CPA, CPA | Chief Financial Officer | 1958 |
| Mr. Joshua N. Silverman | Interim CEO, Interim Pres & Interim Chairman | 1970 |
| Dr. Jose L. Iglesias M.D. | Consulting Chief Medical Officer | 1957 |
| Dr. Hans-Peter Hammes | Member of Medical & Scientific Advisory Board and Consultant | NA |
| Mr. Joshua N. Silverman | Interim CEO, President & Director | 1970 |
| Mr. Joshua N. Silverman | CEO. President & Executive Chairman | 1970 |
| Mr. Carlos A. Trujillo CPA | Chief Financial Officer | 1958 |
| Dr. Hans-Peter Hammes M.D. | Member of Medical & Scientific Advisory Board and Consultant | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.